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Abstract  
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus, and its infection, 
coronavirus disease 2019 (COVID-19), have quickly become a worldwide threat. It is essential for clinicians to 
learn about this pandemic to manage patients. Among different aspects of the condition, is the treatment of 
this disease. Unfortunately, currently there is no effective treatment option that can be supported by evidence-
based medicine. This review analyzes information from literature on treatments. 
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CONTEXT
In December 2019, a novel coronavirus was 
identified as the causative agent for outbreak of 
pneumonia. The virus was named severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
and the disease was subsequently termed COVID-
19. The World Health Organization (WHO) 
declared the disease a pandemic, with 4 million 
infected people and about 300 thousand deaths 
worldwide. Currently, there is no consistent 
evidence from randomized clinical trials for any 
potential therapy. There is no data available for any 
prophylactic therapy. While there are many clinical 
trials under way, this narrative review summarizes 
proposed treatment options for COVID-19.  
 
Anti-viral agents  
 Atazanavir 
Atazanavir is an antiretroviral protease inhibitor, 
which is used for the treatment of human 
immunodeficiency virus 1 (HIV-1) infection. 
Atazanavir can cause transient and usually 
asymptomatic elevation in serum liver enzymes, 
mild elevation in indirect bilirubin level and, rarely, 
clinically apparent, acute liver injury. The antiviral 
medicine is available as 100 and 300 mg capsules. 
Atazanavir was proposed to exert an inhibitory 
effect on SARS-CoV-2 by its antiretroviral protease. 
An artificial intelligence model showed that 
atazanavir has a potential binding affinity to 
multiple components of the coronavirus (e.g. RNA 
polymerase, helicase), suggesting that replication 
of many subunits of the virus may be inhibited by 
atazanavir (1). It should be noted that, this 
medication has binding affinity for some proteins 
of SARS-CoV-2 (e.g. 3C-like proteinase) and the 
replication complex components (1). The data 
suggest that atazanavir and atazanavir/ritonavir 
could be considered as an option to fight against 
COVID-19 (2). 
 Lopinavir/ritonavir 
Lopinavir/ritonavir (400 mg and 100 mg, 
respectively), known as Kaletra, is an HIV-1 
aspartate protease inhibitor, which is used in 
combination with other antiretroviral medicines to 
treat HIV-1 infection in patients older than 14 days. 
Lopinavir/ritonavir could create pancreatitis and 
liver problems. Healthcare providers should 
monitor the liver function using tests before and 
during treatment. Lopinavir/ritonavir is shown to 
have in vitro inhibitory activity against SARS virus 
and Middle East respiratory syndrome coronavirus 
(MERS-CoV), and case reports have suggested that 
its combination with ribavirin and interferon alfa 
results in virologic clearance and survival. The 
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results are not consistent regarding the treatment 
of COVID-19. While a systematic review showed 
that use of lopinavir/ritonavir has some effects in 
the early phase of the disease, a trial on 199 
hospitalized COVID-19 patients found no decrease 
in mortality or time to clinical improvement (3). 
 Remdesivir 
The nucleoside analogue GS-5734 (Remdesivir) 
has been reported to potently inhibit 
coronaviruses in vitro and in a SARS-CoV mouse 
model (4). Clinical trials on this antiviral agent in 
treatment of Ebola are currently underway. It 
seems that remdesivir has acceptable clinical 
safety, based on comparisons between healthy 
volunteers and patients treated for Ebola (5). It has 
been shown that combination of remdesivir and 
chloroquine can be highly effective against COVID-
19 in vitro (6). In a cohort study on 53 hospitalized 
patients with severe COVID-19, who were treated 
with at least one dose of remdesivir, clinical 
improvement has been observed in 68% patients 
(7). In a clinical trial, it was shown that time to 
recovery of patients in remdesivir treatment arm 
decreased from 15 to 11 days. It has also been 
stated that mortality rate was also lower in 
remdesivir treatment arm, though the difference 
was not significant (8).  
 Favipiravir 
Favipiravir (discovered by Toyama Chemical Co., 
Ltd for influenza treatment) is an antiviral 
medicine that selectively inhibits RNA polymerase 
of some RNA viruses (9). This antiviral agent has 
been approved for use against influenza infections 
in 2020. Since COVID-19 is caused by an RNA virus, 
favipiravir may have potential therapeutic effects 
on this disease (10). In a study, the clinical response 
of 7 days of favipiravir treatment was compared to 
arbidol. According to the results of the study, no 
significant difference was observed; however, 
favipiravir could decrease the duration of fever and 
cough (5).  
 Arbidol 
Arbidol is a non‐nucleoside antiviral agent that has 
been approved for influenza treatment in Russia 
and China in 1990 (11). Arbidol has been 
recommended in the Guidelines for the Prevention, 
Diagnosis, and Treatment of Novel Coronavirus-
induced Pneumonia issued by the National Health 
Commission (NHC) of the People’s Republic of 
China. The treatment regimen has proposed a 200 
mg dose in adults, 3 times/day for a maximum of 
10 days (10). Arbidol is mostly excreted in the bile. 
Allergic reactions, nausea, diarrhea, dizziness and 
elevated serum transaminase are the main adverse 
effects of arbidol (12). 
 Sofosbuvir 
This nucleotide analog has been approved for 
Hepatitis C virus infection, and has many 
advantages including high potency, few side effects, 
and oral preparation (13). In the third month of the 
novel Coronavirus epidemic in Wuhan, the use of 
sofosbuvir alongside other antiviral agents such as 
remdesivir was suggested for COVID-19 treatment 
(14). A clinical trial is currently performed in Iran, 
comparing the clinical response to sofosbuvir plus 
daclatasvir regimen with routine care in treatment 
of 70 moderate to severe patients with COVID-19 
(15). 
 Chloroquine and Hydroxychloroquine 
Chloroquine and Hydroxychloroquine are well-
known and old medications that are used for 
treatment and prophylaxis of malaria and for 
chronic inflammatory diseases, such as systemic 
lupus erythematous and rheumatoid arthritis (16, 
17). An important therapeutic effect of these two is 
the immunomodulatory effect, which is due to 
different mechanisms, such as decreasing cytokine 
production, interference with lysosomal 
acidification, and reducing antigen presentation (17, 
18). According to in vitro studies, these medications 
can have antiviral effects through prevention of 
viral fusion and cell entrance (19). In this regard, 
many have endorsed the application of these 
medications even before robust studies. They have 
recommended consuming 500 mg of chloroquine 
orally once or twice daily and 400 to 800 mg of 
hydroxychloroquine per day (17, 20, 21). Until now, the 
results of only two studies have been released. In a 
study, treatment with hydroxychloroquine (600 
mg/day) was able to speed up the clearance of 
virus (21). But the results were questioned because 
of several methodological flaws. Another trial was 
performed in china, but it did not show any 
effectiveness in treatment arm. While the 
medications have acceptable safety profile, 
including during pregnancy, they should be used 
cautiously due to resource allocation and risk of 
ventricular tachycardia due to QT-prolongation (16, 
22). Although there are some studies with promising 
results in the pipeline, their prescription is not 
justifiable at the moment based on evidence-based 
medicine (23).  
Immunomodulators 
Inflammatory cytokines and chemokines (e.g. 
interleukin-6, interleukin-1β) are significantly 
elevated in COVID-19 patients (24). It has been 
proposed that coronavirus dysregulates the 
immune response, mainly by acting on T-cell 
lymphocytes (25). In this way, reducing 
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inflammation would improve patient outcomes. So, 
the effects of some drugs are currently being 
investigated for this purpose (26-28). However, 
reducing the systemic inflammatory response in 
patients with critical condition could have 
detrimental effects due to severe secondary 
infections (29-31). Therefore, it is not considered as 
first approach in this population and should be 
approached with caution. 
 TNF antagonist 
Tumor necrosis factor (TNF) antagonists (i.e. 
infliximab or adalimumab) are widely used for the 
treatment of rheumatologic diseases and 
inflammatory bowel disease (IBD) (32-35). Although 
cytokine inhibition might be considered equal to 
‘immune suppression’ and concluded to be harmful 
in the COVID-19, these agents neutralize mediators 
in the inflammation cascade rather than leading to 
broad immune suppression (36). Previous studies 
have shown that clinical exposure to thiopurines in 
patients with active IBD might increase the risk of 
viral infections (37, 38). However, this is not the case 
regarding coronaviruses in IBD patients (39-42). In 
IBD, use of steroids results in a higher risk of 
infection in comparison to anti-TNFα 
administration (41, 42). The most appropriate time to 
start an immunomodulatory treatment is also on 
discussion.  
 Anti-IL6 antibody 
IL-6 is one of the cytokines that play a pivotal role 
in activation of macrophages and the generation of 
T helper 17 cells (43). In this view, elevated IL-6 
serves as a predictor of disease severity (44). In 
rheumatoid arthritis, TNF blockage would results 
in a rapid decline of IL-6 and IL-1 concentrations in 
patients (45). In addition, reduction in adhesion 
molecules and vascular endothelial growth factor 
(i.e. vascular permeability factor) signifies its 
importance in alveolar-capillary blood-gas 
exchange dysfunction (46-48). Tocilizumab, an anti-
IL‐6R recombinant humanized monoclonal 
antibody, binds IL‐6R and inhibits signaling (49). 
After treatment with tocilizumab, 69% of patients 
responded with fever and hypotension resolution 
within hours and vasopressors could be weaned in 
days (50). The most common serious adverse effect 
is infection among patients with chronic 
maintenance therapy (51). In addition, there is a 
possible medication-related risk of osteonecrosis 
in the jaws (52). COVID-19 patients in critical 
conditions are susceptible to secondary infection 
especially those who have  comorbid chronic 
infections (e.g. hepatitis B and tuberculosis) (44). A 
study showed that IL-6 levels were significantly 
elevated in COVID-19 patients with considerably 
varying degrees among both ICU and non-ICU 
patients (53). Although IL-6 level, alone, may not be 
sufficient to reflect its function, this finding raises 
the question whether IL-6 blockade is only 
effective in patients with elevated serum IL-6 
levels. In this view, C-reactive protein (CRP), is 
proposed as a reliable marker of IL-6 bioactivity 
and is used to monitor IL-6 blockade efficacy (51, 52, 
54, 55). Although several trials on tocilizumab are 
currently underway, initial reports on 21 severe 
and critical COVID-19 patients in China  and a case 
study from France  showed the clinical benefit of 
tocilizumab in COVID-19 (56, 57). 
 Intravenous immunoglobulin 
Intravenous immunoglobulin (IVIG) contains more 
than 95% unmodified immunoglobulin G (IgG) and 
only trace amounts of IgA or IgM the IgG (58). This 
product performs multiple immunomodulating 
activities including complement activation, 
antibody suppression, macrophage Fc receptor 
saturation, and inflammatory mediator 
suppression (59). IVIG is used to treat various 
infectious, autoimmune, and idiopathic diseases. 
There is a report on 3 patients with COVID-19, who 
received high-dose IVIG (25 g/d for 5 days) at the 
time of initiation of respiratory distress, which 
resulted in clinical and radiographic recovery (60). 
However, due to lack of sufficient data, guidelines 
on the management of adults with COVID-19 
suggest against the routine use of this medication 
(61). 
 Corticosteroids 
Corticosteroids are well-known anti-inflammatory 
agents, which are sometimes prescribed for 
treating COVID-19 patients in the ICU (62). Several 
studies had reported outcomes of SARS, MERS, and 
influenza patients treated with corticosteroids. In 
an RCT performed on 17 patients in 2004, early 
intravenous hydrocortisone was used. The results 
showed that initiation of corticosteroid during viral 
replication, in the first week of illness, resulted in 
delayed viral clearance and a higher subsequent 
plasma viral load. As a result, the patients are more 
likely to require mechanical ventilation, 
vasopressors, and renal replacement therapy (63). A 
retrospective observational study on 309 adults, 
who were critically ill with MERS, revealed similar 
results (49). A 2019 systematic review and meta-
analysis found increased mortality in influenza 
patients who were given corticosteroids (64). In a 
study on 41 COVID-19 patients, 21% received 
corticosteroids and showed decreased lung 
inflammation (65). Another concern regarding 
corticosteroids is their short- and long-term 
adverse effects. In a retrospective study on those 
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with SARS, 36.3% of the patients were diagnosed 
with corticosteroid-induced diabetes and more 
than 50% suffered from joint pain and bone 
marrow abnormalities after treatment (66, 67). 
Methylprednisolone dose varies depending on 
disease severity. Current interim guidance from the 
WHO  and Chinese guidelines on COVID-19 
treatment, advise against the use of corticosteroids 
(53, 68). However, according to our clinical 
experience, corticosteroids could/should only be 
prescribed at the right time and for the right 
patients. 
 Cyclosporine, Tacrolimus 
Cyclosporine (CSA) and Tacrolimus (TAC) are 
calcineurin inhibitors. They inhibit production and 
release of interleukin II and induce activation of T-
lymphocytes. They are used in many 
rheumatologic diseases such as Crohn's disease, 
rheumatoid arthritis, psoriasis and also 
in nephrotic syndrome and in organ transplants (69, 
70). CSA also inhibits replication of some viruses but 
it has not been specifically tested in COVID-19 
patients. Based on a meta-analysis, there are 
reports of sustained virological response rates with 
both medications; however, firm conclusion cannot 
be drawn (71). While there is an ongoing clinical trial 
on TAC, the data on these medications is 
insufficient (72). 
Others 
 Plasma treatment  
In the treatment of COVID-19 patients with severe 
symptoms such as shortness of breath, decreased 
level of consciousness, decreased O2 saturation, 
tachypnea, underlying diseases such as diabetes or 
heart disease, age over 65 years, and severe 
respiratory distress in ICU-admitted patients, one 
of the recommended treatments is to use plasma 
transfusion (73, 74). Accordingly, plasma donation is 
encouraged by FDA and is being performed in Iran 
and in many other medical centers around the 
world, including Turkey, China, and many 
European countries. In a study by Cortegiani et al., 
a recovered patient's plasma was transfused to 5 
intubated patients with high viral load. All patients 
were receiving routine antiviral drugs and they had 
a very poor general condition; severe respiratory 
distress with decrease in saturation. After 12 days 
of plasma transfusion, the oxygenation condition 
improved and the virus load decreased along with 
the severity of the disease (75). In another study by 
Duan et al. in China, 10 patients with severe COVID-
19 (6 men and 4 women) with the average age of 
52 years were treated with plasma. All had severe 
illness and three were under mechanical 
ventilation. In addition to respiratory support and 
maintenance therapy, all patients were receiving 
antiviral therapy include arbidol, ribavirin, or 
remdesivir. Some of these patients also received 
intravenous methylprednisolone 20 mg daily. 
Plasma was extracted from patients who had 
previously improved and had high antibody titer 
(at least1:160). Two hundred cc of plasma was 
transfused to the cases. As a primary outcome, 
patients' clinical symptoms improved significantly 
within 3 days of receiving plasma and showed an 
increase in arterial oxygen saturation, as well as 
improvement in laboratory test results such as 
increase in lymphocyte count and decrease in CRP. 
There were no serious and significant 
complications observed with plasma transfusion. 
In terms of imaging, pulmonary involvement was 
improved within 7 days of receiving plasma. Of 
Note, the viral load became undetectable in 7 out of 
10 patients following plasma administration. It has 
been proposed that plasma transfusion can be 
effective in patients with severe COVID-19 if it is 
performed in the first 14 days (76). However, there 
is no consensus on the volume of transfusion or 
frequency, and duration of treatment. This has to 
be explored in future studies. Currently, plasma 
separation is performed using cell separator.  The 
plasma ABO group of the donor must be compatible 
with recipient and about 200 to 400 cc of plasma is 
extracted, which should be stored at a temperature 
below -40°C. This product should be tested for 
corona virus contamination using techniques such 
as methylene blue, to ensure that the virus is not 
stored in the plasma. Currently, this treatment has 
been used on more than 200 patients in Iran and 
the results will be published soon. 
 Vitamins 
Researchers proposed that vitamin deficiency 
might be harmful in COVID-19 patients as vitamins 
have immuno-modulatory effects and 
downregulate pro-inflammatory cytokines; 
however, treatment can be effective in these 
patients (20, 77). There are no trials on COVID-19 and 
vitamins but there are some recommendations 
based on molecular and physiologic mechanisms. A 
review article in china suggests that vitamin A can 
be considered an option for treatment of the novel 
coronavirus, as it enhances the innate immune 
response. They have stated that vitamin B is also 
important, considering that riboflavin would 
reduce infection with MERS-CoV in human (77). 
Similarly, Kandeel et al. suggest that use of vitamin 
B12 and nicotinamide could help based on 
molecular modeling performed in their study (78). 
Another water‐soluble vitamin, is vitamin C. Its 
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antioxidant effects can protect the cells and tissues 
from damage by oxidative agents (79); therefore, it 
can be a good choice for treating the novel 
coronavirus disease (80). A trial on high-dose 
vitamin C in patients with COVID-19 has begun in 
china (81). Some experts suggest use of vitamin D in 
COVID-19 that may be an opportunity treatment. 
Vitamin D3 has a preventive effect on interstitial 
pneumonitis caused by the pathogens in 
parenchyma of lung, and can also reduce 
inflammatory cytokines (77, 80, 82). 
 Selenium, Zinc, Iron 
There are not any documented trials about 
minerals (e.g. Selenium, Zinc, and Iron) and their 
efficacy in treating COVID-19, but some experts 
suggest the effectiveness of these supplements, 
specially zinc, as it has shown effectiveness against 
the SARS (83, 84). 
 Statins 
Statins are well-known agents with anti-
inflammatory effects used in cardiovascular 
diseases (85). There are hypotheses regarding the 
efficacy of statins in patients with novel corona 
virus. Dashti-Khavidaki et al. suggest using statins 
in patients with COVID-19 and acute cardiac injury. 
Yet, hey do not recommend statins as a routine for 
treatment of these patients (86). 
 Non-steroidal anti-inflammatory drugs 
So far, we do not have any significant evidence pro 
or against use of  NSAIDs and its routine use is not 
recommended in management of COVID-19 (87). 
Many guidelines have not approved NSAIDs for 
treating the novel corona virus (88). 
 ACE-Inhibitors 
There was a hypothesis stating Angiotensin-
converting enzyme (ACE) inhibitors (ACEis) and 
Angiotensin II receptor blockers would upregulate 
the receptor ACE2, which is important to SARS-
CoV-2 entry into cells. According to recently 
published studies, treatment with ACEis does not 
result in increased risk to the patients (88-90). One 
guideline has not recommended stopping use of 
ACEis, unless there is contraindication for patients 
to receive ACEis. They suggest that, if the patients 
have primary indication for using ACEis, it can be 
started (91). 
 Tetracyclines 
There are theories that believe tetracyclines may 
be effective in treatment of the novel corona virus  
but there are no trials or strong evidence (92). 
 Tissue Plasminogen Activator (tPA) 
There is not enough evidence for tPA and its 
efficacy in COVID-19 treatment. In a case series, 
Wang and et al. expressed that tPA may be helpful 
in patients with COVID-19 and acute respiratory 
distress syndrome (ARDS) but more studies are 
needed (93). 
CONCLUSIONS 
WHO clinical management interim guidance 
(March 13, 2020) emphasizes that there is no 
definitive treatment for COVID-19. The guidelines 
emphasize the role of supportive care based on 
disease severity and we have to wait for approved 
treatment options from robust clinical trials for 
further recommendations. 
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